20 results on '"Richter, Manuel Jonas"'
Search Results
2. Relevance of Cor Pulmonale in COPD With and Without Pulmonary Hypertension: A Retrospective Cohort Study
- Author
-
Yogeswaran, Athiththan, Kuhnert, Stefan, Gall, Henning, Faber, Marlene, Krauss, Ekaterina, Rako, Zvonimir A., Keranov, Stanislav, Grimminger, Friedrich, Ghofrani, Hossein Ardeschir, Naeije, Robert, Seeger, Werner, Richter, Manuel Jonas, Tello, Khodr, and Justus Liebig University Giessen
- Subjects
ddc:610 - Published
- 2022
- Full Text
- View/download PDF
3. Pulmonary Hemodynamic Response to Exercise in Chronic Thromboembolic Pulmonary Hypertension before and after Pulmonary Endarterectomy
- Author
-
Richter, Manuel Jonas, Sommer, Natascha, Gall, Henning, Voswinckel, Robert, Seeger, Werner, Mayer, Eckhard, Wiedenroth, Christoph B., Rieth, Andreas, Grimminger, Friedrich, Guth, Stefan, and Ghofrani, Hossein A.
- Published
- 2015
- Full Text
- View/download PDF
4. Clinical Relevance of Right Atrial Functional Response to Treatment in Pulmonary Arterial Hypertension
- Author
-
Richter, Manuel Jonas, Zedler, Daniel, Berliner, Dominik, Douschan, Philipp, Gall, Henning, Ghofrani, Hossein Ardeschir, Kimmig, Lucas, Kremer, Nils, Olsson, Karen Maria, Brita da Rocha, Bruno, Rosenkranz, Stephan, Seeger, Werner, Yogeswaran, Athiththan, Rako, Zvonimir A., Tello, Khodr, and Justus Liebig University Giessen
- Subjects
ddc:610 - Published
- 2021
- Full Text
- View/download PDF
5. Application and Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio in Patients with Ischemic and Non-Ischemic Cardiomyopathy
- Author
-
Keranov, Stanislav, Haen, Saskia, Vierheer, Julia-Mareen, Rutsatz, Wiebke, Wolter, Jan Sebastian, Kriechbaum, Steffen D., Jeinsen, Beatrice von, Bauer, Pascal, Tello, Khodr, Richter, Manuel Jonas, Dörr, Oliver, Rieth, Andreas, Nef, Holger, Hamm, Christian, Liebetrau, Christoph, Rolf, Andreas, Keller, Till, and Justus Liebig University Giessen
- Subjects
ddc:610 - Published
- 2021
- Full Text
- View/download PDF
6. Physical Activity and Mental Health of Patients with Pulmonary Hypertension during the COVID-19 Pandemic
- Author
-
Dobler, Carolin Leoni, Krüger, Britta, Strahler, Jana, Weyh, Christopher, Gebhardt, Kristina, Tello, Khodr, Ghofrani, Hossein Ardeschir, Sommer, Natascha, Gall, Henning, Richter, Manuel Jonas, and Krüger, Karsten
- Subjects
active lifestyle ,lcsh:R ,infection control measure ,lcsh:Medicine ,stress levels ,resilience ,Article ,self-quarantine - Abstract
The aim of the study was to analyze the effect of personal restrictions on physical activity, mental health, stress experience, resilience, and sleep quality in patients with pulmonary hypertension (PH) during the &ldquo, lockdown&rdquo, period of the COVID-19 pandemic. In total, 112 PH patients and 52 age-matched healthy control subjects completed a questionnaire on the topics of physical activity, mental health, resilience, and sleep quality. PH patients had significantly lower physical activity, mental health, and sleep quality compared to age-matched healthy controls. Physical activity positively correlated with mental health and sleep quality in the PH group. Mental wellbeing and life satisfaction could be predicted by total physical activity, sleep, stress level, and resilience. PH patients appeared as an especially vulnerable group, demanding interventions to promote an active lifestyle and protect mental health in these patients. This could be helpful in counseling on how to carry out physical activity while maintaining infection control.
- Published
- 2020
7. The Prognostic Significance of Inspiratory Capacity in Pulmonary Arterial Hypertension
- Author
-
Richter, Manuel Jonas, Tiede, Henning, Morty, Rory E., Voswinckel, Robert, Seeger, Werner, Schulz, Richard, Ghofrani, Hossein Ardeschir, and Reichenberger, Frank
- Published
- 2014
- Full Text
- View/download PDF
8. Increased frequency of the restless legs syndrome in adults with cystic fibrosis
- Author
-
Jurisch, Peter, Gall, Henning, Richter, Manuel Jonas, Seeger, Werner, Nährlich, Lutz, Völkel, Sebastian, Hirche, Tim Oliver, and Schulz, Richard
- Published
- 2019
- Full Text
- View/download PDF
9. Doppler-Derived Renal Venous Stasis Index in the Prognosis of Right Heart Failure
- Author
-
Husain-Syed, Faeq, Birk, Horst-Walter, Ronco, Claudio, Schörmann, Tanja, Tello, Khodr, Richter, Manuel Jonas, Wilhelm, Jochen, Sommer, Natascha, Steyerberg, Ewout W., Bauer, Pascal, Walmrath, Hans-Dieter, Seeger, Werner, McCullough, Peter A., Gall, Henning, Ghofrani, Hossein Ardeschir, and Justus Liebig University Giessen
- Subjects
ddc:610 - Published
- 2019
- Full Text
- View/download PDF
10. Atrial fibrillation as a rare clinical presentation of a bronchogenic cyst
- Author
-
Zaatar, Mohamed, Wiedenroth, Christoph B., Richter, Manuel Jonas, Mayer, Eckhard, and Beqiri, Safet
- Subjects
ddc: 610 ,fungi ,610 Medical sciences ,Medicine - Abstract
Background: Bronchogenic cysts are mostly benign, congenital foregut malformations. They can be found in any organ, but most frequently in the chest cavity, especially mediastinal and intrapulmonary. Most patients are asymptomatic. We present a case of a subcarinal bronchogenic cyst with a rare clinical[for full text, please go to the a.m. URL], 133. Kongress der Deutschen Gesellschaft für Chirurgie
- Published
- 2016
11. The Clinical Significance of HbA1c in Operable Chronic Thromboembolic Pulmonary Hypertension
- Author
-
Richter, Manuel Jonas, Milger, Katrin, Haase, Sarah, Sommer, Natascha, Tello, Khodr, Seeger, Werner, Mayer, Eckhard, Wiedenroth, Christoph Benjamin, Grimminger, Friedrich, George, Wolfgang, Ghofrani, Hossein Ardeschir, Guth, Stefan, Gall, Henning, and Department of Internal Medicine
- Subjects
Male ,Pulmonology ,lcsh:Medicine ,Biochemistry ,Cohort Studies ,Endocrinology ,Glucose Metabolism ,Natriuretic Peptide, Brain ,Diabetes diagnosis and management ,Prospective Studies ,Pulmonary Arteries ,lcsh:Science ,Immunoassay ,Pulmonary Hypertension ,Hematology ,Arteries ,Middle Aged ,Plants ,Prognosis ,Legumes ,Creatinine ,Carbohydrate Metabolism ,Female ,Anatomy ,Research Article ,HbA1c ,Endocrine Disorders ,Hypertension, Pulmonary ,Endarterectomy ,Pulmonary Artery ,Diabetes Mellitus ,Humans ,Arterial Pressure ,ddc:610 ,Hemoglobin ,Aged ,Glycated Hemoglobin ,Medicine and health sciences ,Biology and life sciences ,lcsh:R ,Hemodynamics ,Organisms ,Peas ,Proteins ,Medical sciences Medicine ,Peptide Fragments ,Diagnostic medicine ,Logistic Models ,Metabolism ,Metabolic Disorders ,Chronic Disease ,Cardiovascular Anatomy ,Blood Vessels ,lcsh:Q ,Biomarkers - Abstract
Background: Glycosylated hemoglobin A1c (HbA1c) has been proposed as an independent predictor of long-term prognosis in pulmonary arterial hypertension. However, the clinical relevance of HbA1c in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) remains unknown. The aim of the present study was to investigate the clinical significance of HbA1c as a biomarker in CTEPH. Methods: Prospectively, 102 patients underwent pulmonary endarterectomy (PEA) in our national referral center between March 2013 and March 2014, of which after exclusion 45 patients were analyzed. HbA1c- levels, hemodynamic and exercise parameters were analyzed prior and one-year post-PEA. Results: 45 patients (BMI: 27.3 ± 6.0 kg/m2; age: 62.7 ± 12.3 years) with a mean pulmonary arterial pressure (mPAP) of 43.6 ± 9.4 mmHg, a pulmonary vascular resistance (PVR) of 712.1 ± 520.4 dyn*s/cm5, a cardiac index (CI) of 2.4 ± 0.5 l/min/m2 and a mean HbA1c-level of 39.8 ± 5.6 mmol/mol were included. One-year post-PEA pulmonary hemodynamic and functional status significantly improved in our cohort. Baseline HbA1c-levels were significantly associated with CI, right atrial pressure, peak oxygen uptake and the change of 6-minute walking distance using linear regression analysis. However, using logistic regression analysis baseline HbA1c-levels were not significantly associated with residual post-PEA PH. Conclusions: This is the first prospective study to describe an association of HbA1c-levels with pulmonary hemodynamics and exercise capacity in operable CTEPH patients. Our preliminary results indicate that in these patients impaired glucose metabolism as assessed by HbA1c is of clinical significance. However, HbA1c failed as a predictor of the hemodynamic outcome one-year post-PEA.
- Published
- 2016
12. Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion
- Author
-
Tello, Khodr, Hoffmann, Andreas, Beutel, Björn, Greulich, Timm, Vogelmeier, Claus Franz, Richter, Manuel Jonas, Kuhnert, Stefan, Böselt, Tobias, Alter, Peter, Holland, Angelique, Idzko, Marco, Buhl, Roland, and Koczulla, Andreas Rembert
- Published
- 2019
- Full Text
- View/download PDF
13. Immune-regulating effects of exercise on cigarette smoke-induced inflammation.
- Author
-
Madani, Ashkan, Alack, Katharina, Richter, Manuel Jonas, and Krüger, Karsten
- Subjects
CIGARETTE smoke ,EXERCISE physiology ,INFLAMMATION ,STROKE risk factors ,PHYSICAL activity ,OXIDATIVE stress - Abstract
Long-term cigarette smoking (LTCS) represents an important risk factor for cardiac infarction and stroke and the central risk factor for the development of a bronchial carcinoma, smoking-associated interstitial lung fibrosis, and chronic obstructive pulmonary disease. The pathophysiologic development of these diseases is suggested to be promoted by chronic and progressive inflammation. Cigarette smoking induces repetitive inflammatory insults followed by a chronic and progressive activation of the immune system. In the pulmonary system of cigarette smokers, oxidative stress, cellular damage, and a chronic activation of pattern recognition receptors are described which are followed by the translocation of the NF-kB, the release of pro-inflammatory cytokines, chemokines, matrix metalloproteases, and damage-associated molecular patterns. In parallel, smoke pollutants cross directly through the alveolus-capillary interface and spread through the systemic bloodstream targeting different organs. Consequently, LTCS induces a systemic low-grade inflammation and increased oxidative stress in the vascular system. In blood, these processes promote an increased coagulation and endothelial dysfunction. In muscle tissue, inflammatory processes activate catabolic signaling pathways followed by muscle wasting and sarcopenia. In brain, several characteristics of neuroinflammation were described. Regular exercise training has been shown to be an effective nonpharmacological treatment strategy in smoke-induced pulmonary diseases. It is well established that exercise training exerts immune-regulating effects by activating anti-inflammatory signaling pathways. In this regard, the release of myokines from contracting skeletal muscle, the elevations of cortisol and adrenalin, the reduced expression of Toll-like receptors, and the increased mobilization of immune-regulating leukocyte subtypes might be of vital importance. Exercise training also increases the local and systemic antioxidative capacity and several compensatory mechanisms in tissues such as an increased anabolic signaling in muscle or an increased compliance of the vascular system. Accordingly, regular exercise training seems to protect long-term smokers against some important negative local and systemic consequences of smoking. Data suggest that it seems to be important to start exercise training as early as possible. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. Short-term venoarterial extracorporeal membrane oxygenation for massive endobronchial hemorrhage after pulmonary endarterectomy.
- Author
-
Guth, Stefan, Wiedenroth, Christoph B., Wollenschläger, Marc, Richter, Manuel Jonas, Ghofrani, Hossein A., Arlt, Matthias, and Mayer, Eckhard
- Abstract
Objectives Pulmonary endarterectomy (PEA) is the only curative treatment option for patients with chronic thromboembolic pulmonary hypertension. Massive endobronchial bleeding that precludes weaning from cardiopulmonary bypass is an often-fatal complication of PEA. The aim of this study was to determine whether short-term extracorporeal membrane oxygenation (ECMO) is a safe and feasible procedure in patients with severe endobronchial bleeding. Methods From January 2014 to December 2016, 396 patients (mean age 60 ± 18 years, 54.5% male) underwent PEA in our department. Patients with severe endobronchial hemorrhage at the time of weaning from cardiopulmonary bypass (CPB) were switched to a heparin-coated venoarterial ECMO circuit. After full-dose protamine administration to restore normal coagulation, weaning from ECMO was attempted in the operating room. Results In-hospital mortality was 2.3% (9/396 patients). Eight patients (2.0%) developed severe endobronchial bleeding classified as diffuse (n = 6) or localized (n = 2) by bronchoscopy. After reinstitution of CPB and subsequent switch to ECMO, the mean duration of ECMO support was 49 ± 13 minutes, and all 8 patients were weaned successfully from ECMO in the operating theater without further signs of endobronchial bleeding. One patient needed venovenous ECMO support for poor oxygenation 6 hours after surgery. Seven patients were discharged after a prolonged postoperative stay of 17.6 ± 4.1 days. One patient died. This new concept significantly reduced mortality compared with previous (2009-2013) ECMO support ( P = .0406). Conclusions For patients with massive endobronchial bleeding after PEA, the intraoperative switch from CPB to venoarterial ECMO support with full-dose protamine administration is a new and potentially life-saving treatment concept. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. Hemodynamic phenotyping based on exercise catheterization predicts outcome in patients with heart failure and reduced ejection fraction.
- Author
-
Rieth, Andreas, Richter, Manuel Jonas, Gall, Henning, Seeger, Werner, Ghofrani, Hossein A., Mitrovic, Veselin, and Hamm, Christian W.
- Subjects
- *
EXERCISE physiology , *HEART failure , *CARDIAC catheterization , *HEMODYNAMICS , *PHENOTYPES , *PROGNOSIS - Abstract
Background Exercise right heart catheterization (RHC) unmasks different phenotypes based on hemodynamic response to exertion in patients with heart failure. The prognostic relevance of this approach in patients with heart failure and reduced ejection fraction (HFrEF) is uncertain. Methods We analyzed 167 patients with HFrEF from the Kerckhoff-Klinik Heart Failure Registry who underwent supine exercise RHC with constant external workload between September 2009 and August 2014. The primary outcome was heart transplant/assist device–free survival. Hemodynamic parameters that significantly predicted outcome were identified by multivariate Cox regression analysis and assessed further by Kaplan-Meier analysis after dichotomization using cutoffs derived from receiver operating characteristic analysis. Hemodynamic phenotypes were defined based on a dichotomized flow response (exercise-induced change in cardiac output [∆CO]) combined with a dichotomized pressure response (exercise-induced change in systolic [∆sPAP] or mean pulmonary arterial pressures). Results ∆CO independently predicted transplant/assist device–free survival (multivariate hazard ratio [HR] 1.67; 95% confidence interval [CI], 1.09–2.58; p = 0.02). Patients with ∆CO ≥1.15 liter/min had significantly better 5-year transplant/assist device–free survival than patients with lower ∆CO (72.9% vs 22.5%; log-rank p < 0.001 [Kaplan-Meier analysis]). The hemodynamic phenotype of ∆CO <1.15 liter/min combined with ∆sPAP <17.5 mm Hg was associated with worse transplant/assist device–free survival than ∆CO ≥1.15 liter/min combined with ∆sPAP ≥17.5 mm Hg (multivariate HR 7.39; 95% CI, 2.27–24.05; p = 0.001). Conclusions Exercise RHC parameters are important prognostic indices in HFrEF. Hemodynamic phenotyping using ∆CO and ∆sPAP allows enhanced risk stratification. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension.
- Author
-
Richter, Manuel Jonas, Tiede, Svenja Lena, Sommer, Natascha, Schmidt, Thomas, Seeger, Werner, Ghofrani, Hossein Ardeschir, Schermuly, Ralph, and Gall, Henning
- Subjects
- *
PULMONARY hypertension diagnosis , *PULMONARY hypertension , *ANGIOPOIETIN-1 , *SEVERITY of illness index , *BIOMARKERS , *LONGITUDINAL method , *PROGNOSIS - Abstract
Background: Circulating angiopoietin-1 (Ang-1) has been linked to pulmonary hypertension (PH) in experimental studies. However, the clinical relevance of Ang-1 as a biomarker in PH remains unknown. We aimed to investigate the prognostic and clinical significance of Ang-1 in PH using data from the prospectively recruiting Giessen PH Registry. Methods: Patients with suspected PH (without previous specific pulmonary arterial hypertension [PAH] therapy) who underwent initial right heart catheterization (RHC) in our national referral center between July 2003 and May 2012 and who agreed to optional biomarker analysis were included if they were diagnosed with idiopathic PAH, connective tissue disease-associated PAH (CTD-PAH), PH due to left heart disease (PH-LHD), or chronic thromboembolic PH (CTEPH), or if PH was excluded by RHC (non-PH controls). The association of Ang-1 levels with disease severity (6-minute walk distance and pulmonary hemodynamics) was assessed using linear regression, and the impact of Ang-1 levels on transplant-free survival (primary endpoint) and clinical worsening was assessed using Kaplan—Meier curves, receiver operating characteristic (ROC) analyses, and Cox regression. Results: 151 patients (39, 39, 32, and 41 with idiopathic PAH, CTD-PAH, PH-LHD, and CTEPH, respectively) and 41 non-PH controls were included. Ang-1 levels showed no significant difference between groups (p = 0.8), and no significant associations with disease severity in PH subgroups (p ≥ 0.07). In Kaplan—Meier analyses, Ang-1 levels (stratified by quartile) had no significant impact on transplant-free survival (p ≥ 0.27) or clinical worsening (p ≥ 0.51) in PH subgroups. Regression models found no significant association between Ang-1 levels and outcomes (p ≥ 0.31). ROC analyses found no significant cut-off that would maximize sensitivity and specificity. Conclusions: Despite a strong pathophysiological association in experimental studies, this first comprehensive analysis of Ang-1 in PH subgroups suggests that Ang-1 is not a predictive and clinically relevant biomarker in PH. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
17. Heart rate response during 6-minute walking testing predicts outcome in operable chronic thromboembolic pulmonary hypertension.
- Author
-
Richter, Manuel Jonas, Milger, Katrin, Tello, Khodr, Stille, Philipp, Seeger, Werner, Mayer, Eckhard, Ghofrani, Hossein A., and Gall, Henning
- Subjects
WALKING ,WALKING speed ,HYPERTENSION ,HEMODYNAMICS ,HEMORHEOLOGY ,ARTERIES ,BLOOD pressure ,CHRONIC diseases ,ECHOCARDIOGRAPHY ,ENDARTERECTOMY ,HEART beat ,LONGITUDINAL method ,VASCULAR resistance ,MULTIVARIATE analysis ,PULMONARY artery ,PULMONARY hypertension ,REGRESSION analysis ,THROMBOEMBOLISM ,LOGISTIC regression analysis ,OXYGEN consumption ,DISEASE complications - Abstract
Background: Six-minute walk test (6MWT) is routinely performed in chronic thromboembolic pulmonary hypertension (CTEPH) before pulmonary endarterectomy (PEA). However, the clinical relevance of heart rate response (ΔHR) and exercise-induced oxygen desaturation (EID) during 6MWT is remaining unknown.Methods: Patients undergoing PEA in our center between 03/2013-04/2014 were assessed prospectively with hemodynamic and exercise parameters prior to and 1 year post-PEA. Patients with symptomatic chronic thromboembolic disease (mean pulmonary artery pressure (mPAP) <25 mmHg) and clinical relevant obstructive pulmonary disease were excluded. The following definitions were used: ΔHR = (peak HR - resting HR), percent heart rate reserve (HRR) = (peak HR -rest HR)/(220 - age - rest HR) x 100 and EID = SpO2 ≤88 %.Results: Thirty-seven patients (of 116 patients screened) with mPAP of 43.2 ± 8.7 mmHg, pulmonary vascular resistance (PVR) of 605.5 ± 228.7 dyn*s/cm(5), cardiac index (CI) of 2.4 ± 0.5 l/min/m(2) and a 6MWT-distance of 404.7 ± 148.4 m and a peak VO2 of 12.3 ± 3.4 ml/min/kg prior to PEA were included. Baseline ΔHR during 6MWT was significantly associated with PVR 1 year post-PEA using linear regression analysis (r = 0.43, p = 0.01). Multivariate analysis indicated an association of HRR during 6MWT and residual PH with a hazard ratio of 1.06 (95 % Confidence interval for hazard ratio 0.99-1.14, p = 0.08). EID was observed commonly during 6MWT but no correlations to outcome parameters were found.Conclusions: This is the first prospective study to describe an association of ΔHR during 6MWT with pulmonary hemodynamics 1 year post-PEA. Our preliminary results indicate that HRR derived from 6MWT is of clinical significance. EID was commonly observed, albeit failed as a significant prognostic factor. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
18. Evaluation of pulmonary hypertension by right heart catheterisation: does timing matter?
- Author
-
Yogeswaran A, Richter MJ, Sommer N, Ghofrani HA, Seeger W, Gall H, and Tello K
- Subjects
- Cardiac Catheterization, Humans, Pulmonary Artery, Hypertension, Pulmonary diagnosis
- Abstract
Competing Interests: Conflict of interest: A. Yogeswaran reports editorial support from University of Giessen, during the conduct of the study. Conflict of interest: M.J. Richter reports grants from German Research Foundation, editorial support from University of Giessen, during the conduct of the study; grants from United Therapeutics, grants and personal fees for lectures and consultancy from Bayer, personal fees for lectures from Actelion, Mundipharma, Roche and OMT, outside the submitted work. Conflict of interest: N. Sommer reports personal fees from Actelion, outside the submitted work. Conflict of interest: H.A. Ghofrani reports grants from German Research Foundation, editorial support from University of Giessen, during the conduct of the study; personal fees for consultancy and advisory board work from Bayer and Pfizer, personal fees for consultancy, lectures and advisory board work from Actelion and GSK, personal fees for consultancy from Merck, grants and personal fees for consultancy from Novartis, grants and personal fees for lectures from Bayer HealthCare and Encysive/Pfizer, grants from Aires, German Research Foundation, Excellence Cluster Cardiopulmonary Research and German Ministry for Education and Research, personal fees for advisory board work from Takeda, outside the submitted work. Conflict of interest: W. Seeger reports grants from German Research Foundation, editorial support from University of Giessen, during the conduct of the study; personal fees for lectures and consultancy from Pfizer and Bayer Pharma AG, outside the submitted work. Conflict of interest: H. Gall reports grants from German Research Foundation, editorial support from University of Giessen, during the conduct of the study; personal fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer and United Therapeutics, outside the submitted work. Conflict of interest: K. Tello reports grants from German Research Foundation, editorial support from University of Giessen, during the conduct of the study; personal fees for lectures from Actelion and Bayer, outside the submitted work.
- Published
- 2020
- Full Text
- View/download PDF
19. Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension.
- Author
-
Desole S, Richter MJ, Heine A, and Ewert R
- Abstract
Intravenous prostacyclin-based therapy improves survival in children with pulmonary arterial hypertension (PAH), but is typically administered via an external infusion pump, which places a considerable burden on the patient. Implanted pumps may overcome some of the limitations of external pumps. We describe the first long-term use of an implanted pump for intravenous treprostinil delivery in a pediatric patient with PAH. Our patient was experiencing marked dyspnea on exertion despite triple combination therapy with bosentan, sildenafil, and inhaled iloprost. Parenteral prostacyclin-based therapy was discussed and the patient rejected options involving external pumps; she finally chose intravenous treprostinil delivery via an implanted pump (LENUS Pro®; fixed flow rate; 20 ml reservoir). The patient underwent pump implantation in July 2012 (aged 14 years) under general anesthesia with no peri- or postoperative complications. She showed marked improvements in fatigue and dyspnea over the subsequent weeks, and her inhaled iloprost regimen was slowly decreased and stopped after six months. During follow-up, the pump showed an unexpected, progressive increase in flow rate that allowed a treprostinil dose of 170 ng/kg/min to be achieved, but at the cost of shortened intervals between refills. The pump was therefore replaced in August 2017 with a newer model with an adjustable flow rate (Siromedes®). A catheter dislocation was corrected under local anesthesia one week after the replacement surgery. The patient is currently receiving treprostinil 170 ng/kg/min with percutaneous refills every 12-13 days. Thus, implantable pumps might be a valuable alternative to external pumps for treprostinil infusion in pediatric PAH.
- Published
- 2019
- Full Text
- View/download PDF
20. Selexipag for the treatment of pulmonary arterial hypertension.
- Author
-
Richter MJ, Gall H, Grimminger J, Grimminger F, and Ghofrani HA
- Subjects
- Administration, Oral, Animals, Drug Approval, Epoprostenol metabolism, Humans, Acetamides therapeutic use, Hypertension, Pulmonary drug therapy, Pyrazines therapeutic use
- Abstract
Introduction: Targeted pulmonary vasoactive substances are the cornerstone of treatment in pulmonary arterial hypertension (PAH). Approved drugs act on various receptors and molecules within the pulmonary arteries, mainly causing pulmonary vasodilation and potentially reversing remodeling with consequent improvement of right ventricular function. A key role is attributed to the prostacyclin pathway and especially the prostacyclin receptor (IP). Selexipag is a recently developed, non-prostanoid, oral IP receptor agonist for the treatment of PAH which has been approved in countries/regions including the USA and Europe., Areas Covered: We review the discovery and development of drugs targeting IP receptors in PAH and describe preclinical and phase I studies of selexipag. Furthermore, we review important phase II and III selexipag studies and place them into the clinical context of previously approved prostanoids., Expert Opinion: Oral selexipag offers a promising therapeutic option within the class of available drugs targeting IP receptors. However, its role as first-line therapy based on its efficacy/side-effect profile in current studies is questionable. Most likely, selexipag will be used in combination with other PAH-specific oral drugs. The potential of selexipag to replace or postpone the use of inhaled or parenteral prostanoids needs to be investigated in future trials.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.